Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer

Area of Science:

• Oncology
• Nephrology

Background:

• Advanced renal cell cancer (RCC) presents a significant clinical challenge.
• Effective systemic therapies for metastatic RCC are crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the efficacy of combination or single-agent therapy using methyl-CCNU, vinblastine, and medroxyprogesterone in patients with advanced renal cell cancer.
• To identify prognostic factors influencing survival in metastatic RCC.

Main Methods:

• A cohort of 165 patients with advanced renal cell cancer were assessed.
• Treatment regimens included combination therapy and single-agent administration of methyl-CCNU, vinblastine, and medroxyprogesterone.

Main Results:

• A low overall response rate was observed across the treatment groups.
• The studied agents did not demonstrate significant efficacy in treating metastatic renal cell cancer.
• Performance status and a longer symptom-free interval from primary tumor to metastasis were key predictors of survival.

Conclusions:

• Methyl-CCNU, vinblastine, and medroxyprogesterone are not effective treatments for metastatic renal cell cancer.
• Performance status and disease-free interval are critical prognostic indicators for survival in advanced RCC patients.